Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 6,414 | 622 | 5,627 |
| Samples | 764 | 142 | 611 |
| Peptides | 630 | 118 | 524 |
Function
NFATC1 · Nuclear factor of activated T cells 1
The product of this gene is a component of the nuclear factor of activated T cells DNA-binding transcription complex. This complex consists of at least two components: a preexisting cytosolic component that translocates to the nucleus upon T cell receptor (TCR) stimulation, and an inducible nuclear component. Proteins belonging to this family of transcription factors play a central role in inducible gene transcription during immune response. The product of this gene is an inducible nuclear component. It functions as a major molecular target for the immunosuppressive drugs such as cyclosporin A. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. Different isoforms of this protein may regulate inducible expression of different cytokine genes. [provided by RefSeq, Jul 2013].
Isoforms & Proteins
11 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000427363 | O95644 | 817 | 529 |
| ENST00000329101 | O95644-6 | 735 | 491 |
| ENST00000253506 | O95644-4 | 676 | 448 |
| ENST00000318065 | O95644-5 | 672 | 445 |
| ENST00000591814 | O95644-2 | 604 | 392 |
| ENST00000542384 | O95644-10 | 602 | 393 |
| ENST00000592223 | O95644-3 | 601 | 390 |
| ENST00000586434 | O95644-11 | 599 | 391 |
| ENST00000587635 | K7ER53* | 553 | 352 |
| ENST00000545796 | F5H4S8* | 309 | 223 |
| ENST00000397790 | O95644-17 | 246 | 177 |
Gene Properties
Recurrent Mutations
All 529 amino-acid changes on canonical ENST00000427363 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NFATC1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NFATC1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 28/612 5% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Melanoma | 12/210 6% | 69/1899 4% |
| Colorectal Carcinoma | 13/143 9% | 107/3239 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 30/1390 2% |
| Neuroendocrine Tumour | 15/154 10% | 5/577 1% |
| Gastric Carcinoma | 3/74 4% | 48/1809 3% |
| Burkitts Lymphoma | 4/32 12% | 2/196 1% |
| Other Solid Cancers | 5/94 5% | 35/1515 2% |
| Bladder Carcinoma | 2/58 3% | 22/956 2% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 19/810 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Germ Cell Tumour | 1/25 4% | 3/169 2% |
| Ewings Sarcoma | 4/63 6% | 2/262 1% |
| Hepatocellular Carcinoma | 2/46 4% | 35/2210 2% |
| Cervical Carcinoma | 2/35 6% | 5/422 1% |
| Osteosarcoma | 2/45 4% | 1/166 1% |
| Non-Cancerous | 2/104 2% | 11/830 1% |
| Biliary Tract Carcinoma | 0/54 0% | 14/950 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Other Sarcomas | 2/69 3% | 7/699 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 17/1592 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Glioma | 0/52 0% | 20/2127 1% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
Mutation Distribution
Where NFATC1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NFATC1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 6,414 mutations in NFATC1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|